Loading…
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2026
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2026 | $481M | $29M | $2M | $54M | 0.7% | 14.5% | -103.9% |
| 2025 | $420M | $-26M | $-59M | $8M | -22.1% | 17.8% | -57.2% |
| 2024 | $356M | $-104M | $-137M | $-57M | -54.4% | 26.8% | -22.3% |
| 2023 | $281M | $-149M | $-176M | $-116M | -61.2% | - | - |
| 2022 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Total Revenue | - | 280.91 | 356.30 | 419.81 | 480.59 |
| Operating Revenue | - | 280.91 | 356.30 | 419.81 | 480.59 |
| Cost Of Revenue | - | 109.27 | 124.01 | 134.93 | 154.12 |
| Gross Profit | - | 171.64 | 232.29 | 284.88 | 326.47 |
| Operating Expense | - | 348.20 | 368.77 | 342.98 | 333.08 |
| Research And Development | - | 91.24 | 112.35 | 117.36 | 121.48 |
| Selling General And Administration | - | 231.65 | 226.93 | 197.73 | 180.15 |
| Total Expenses | - | 457.46 | 492.78 | 477.91 | 487.20 |
| Operating Income | - | -176.55 | -136.48 | -58.10 | -6.61 |
| Total Operating Income As Reported | - | -176.55 | -136.48 | -58.10 | -6.61 |
| EBITDA | - | -148.95 | -104 | -25.58 | 29.47 |
| Normalized EBITDA | - | -148.95 | -102.88 | -25.58 | 29.97 |
| EBIT | - | -174.25 | -133.49 | -53.46 | -1.99 |
| Interest Income | - | 2.48 | 4.07 | 2.68 | 2.17 |
| Interest Expense | - | 1.41 | 1.85 | 2.35 | 6.95 |
| Net Interest Income | - | 1.06 | 2.21 | 0.33 | -4.78 |
| Other Non Operating Income Expenses | - | -0.18 | 0.04 | 1.96 | 2.95 |
| Other Income Expense | - | -0.18 | -1.07 | 1.96 | 2.45 |
| Interest Income Non Operating | - | 2.48 | 4.07 | 2.68 | 2.17 |
| Interest Expense Non Operating | - | 1.41 | 1.85 | 2.35 | 6.95 |
| Net Non Operating Interest Income Expense | - | 1.06 | 2.21 | 0.33 | -4.78 |
| Pretax Income | - | -175.66 | -135.34 | -55.81 | -8.94 |
| Tax Provision | - | 0.48 | 1.54 | 2.72 | -11.25 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -0.23 | 0 | -0.20 |
| Net Income Continuous Operations | - | -176.15 | -136.88 | -58.53 | 2.31 |
| Net Income From Continuing And Discontinued Operation | - | -176.15 | -136.88 | -58.53 | 2.31 |
| Net Income From Continuing Operation Net Minority Interest | - | -176.15 | -136.88 | -58.53 | 2.31 |
| Net Income | - | -176.15 | -136.88 | -58.53 | 2.31 |
| Net Income Common Stockholders | - | -176.15 | -136.88 | -58.53 | 2.31 |
| Net Income Including Noncontrolling Interests | - | -176.15 | -136.88 | -58.53 | 2.31 |
| Normalized Income | - | -176.15 | -136 | -58.53 | 2.61 |
| Diluted NI Availto Com Stockholders | - | -176.15 | -136.88 | -58.53 | 2.31 |
| Basic Average Shares | - | 52.44 | 54.56 | 57.59 | 59.74 |
| Diluted Average Shares | - | 52.44 | 54.56 | 57.59 | 61.49 |
| Reconciled Depreciation | - | 25.30 | 29.49 | 27.89 | 31.45 |
| Reconciled Cost Of Revenue | - | 109.27 | 124.01 | 134.93 | 154.12 |
| Total Unusual Items | - | 0 | -1.12 | 0 | -0.50 |
| Total Unusual Items Excluding Goodwill | - | 0 | -1.12 | 0 | -0.50 |
| Special Income Charges | - | 0 | -1.12 | 0 | -0.50 |
| Other Special Charges | - | - | 1.12 | - | 0.50 |
| Depreciation Amortization Depletion Income Statement | - | 25.30 | 29.49 | 27.89 | 31.45 |
| Depreciation And Amortization In Income Statement | - | 25.30 | 29.49 | 27.89 | 31.45 |
| General And Administrative Expense | - | 80.38 | 79.93 | 76.60 | 79.90 |
| Other Gand A | - | 80.38 | 79.93 | 76.60 | 79.90 |
| Selling And Marketing Expense | - | 151.26 | 147.01 | 121.13 | 100.24 |
| Otherunder Preferred Stock Dividend | 0 | - | - | - | - |
| Amortization | - | 7.32 | 11.90 | 13.70 | 18.48 |
| Amortization Of Intangibles Income Statement | - | 7.32 | 11.90 | 13.70 | 18.48 |
| Depreciation Income Statement | - | 17.99 | 17.58 | 14.18 | 12.97 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Phreesia, Inc.this co. | PHR | $599M | 259.74↑ premium | 1.78 | 0.7% | 21.30 |
| Prime Medicine, Inc. | PRME | $627M | -3.12 | 5.19 | -166.4% | -3.38 |
| Beta Bionics, Inc. | BBNX | $619M | -8.46 | 2.15 | -25.5% | -8.64 |
| Gyre Therapeutics, Inc. | GYRE | $601M | 119.48 | 5.66 | 4.7% | 40.29 |
| Ginkgo Bioworks Holdings, Inc. | DNA | $591M | -1.89 |
| - |
| - |
| - |
| - |
| 1.16 |
| -61.5% |
| -3.39 |
| Bioventus Inc. | BVS | $589M | 25.93 | 3.20 | 12.3% | 8.39 |
| Altimmune, Inc. | ALT | $568M | -6.45 | 2.53 | -39.2% | -6.43 |
| Tactile Systems Technology, Inc. | TCMD | $568M | 29.74 | 2.59 | 8.7% | 12.42 |
| MiMedx Group, Inc. | MDXG | $563M | 11.59 | 2.19 | 18.9% | 5.27 |
| Peer Median | - | 4.85 | 2.56 | -10.4% | 0.94 | |